Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Long-Term Debt Repayments (2017 - 2023)

Ocular Therapeutix has reported Long-Term Debt Repayments over the past 7 years, most recently at -$24.1 million for Q4 2023.

  • Quarterly results put Long-Term Debt Repayments at -$24.1 million for Q4 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was -$22.0 million (changed N/A YoY), and the annual figure for FY2023 was $2.0 million, changed.
  • Long-Term Debt Repayments for Q4 2023 was -$24.1 million at Ocular Therapeutix, down from $2.1 million in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for OCUL hit a ceiling of $2.1 million in Q2 2021 and a floor of -$24.1 million in Q4 2023.